Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
999 30 |
Ultima descărcare din IBN: 2023-11-02 19:53 |
SM ISO690:2012 GONCIAR, Veaceslav, SCUTAR, Corina, PEREDELCU, Rodica, CAZACU, Vasilii, POPA, Cristina, SCUTARI, Oleg. Unele particularităţi farmacologice ale acidului hialuronic. In: Analele Ştiinţifice ale USMF „N. Testemiţanu”, 2012, nr. 1(13), pp. 211-215. ISSN 1857-1719. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Analele Ştiinţifice ale USMF „N. Testemiţanu” | ||||||
Numărul 1(13) / 2012 / ISSN 1857-1719 | ||||||
|
||||||
Pag. 211-215 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Acidul hialuronic (AH) este recomandat ca remediu medicamentos cu proprietăți reologice, antiinflamatoare, protective, proliferative, imunomodulatoare, pentru stimularea sintezei hemoglobinei şi în calitate de excipient pentru uz topic. Necesităţile mereu crescânde de AH pentru farmaceutică şi cosmetică impun investigaţii în scopul cercetărilor proprietăţilor
farmacologice noi, testării clinice a AH în calitate de substanţă farmaceutică auxiliară pentru elaborarea formelor medicamentoase în asociaţie cu alte substanţe active. |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-18118</cfResPublId> <cfResPublDate>2012-02-01</cfResPublDate> <cfVol>13</cfVol> <cfIssue>1</cfIssue> <cfStartPage>211</cfStartPage> <cfISSN>1857-1719</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/18118</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Unele particularităţi farmacologice ale acidului hialuronic</cfTitle> <cfAbstr cfLangCode='RO' cfTrans='o'>Acidul hialuronic (AH) este recomandat ca remediu medicamentos cu proprietăți reologice, antiinflamatoare, protective, proliferative, imunomodulatoare, pentru stimularea sintezei hemoglobinei şi în calitate de excipient pentru uz topic. Necesităţile mereu crescânde de AH pentru farmaceutică şi cosmetică impun investigaţii în scopul cercetărilor proprietăţilor farmacologice noi, testării clinice a AH în calitate de substanţă farmaceutică auxiliară pentru elaborarea formelor medicamentoase în asociaţie cu alte substanţe active.</cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'>Some pharmacological aspects of hyaluronic acid Hyaluronic acid can be recommended as a drug for external and parenteral use as a rheological, inflammatory, protective, proliferative, immunomodulatory remedy, for stimulating the synthesis of hemoglobin and as an auxiliary pharmaceutical substance for topical use. Ever-growing needs of AH for pharmaceutical and cosmetic properties require pharmacological investigations and new clinical studies of the AH as auxiliary pharmaceutical substance for the elaboration of medicinal forms in association with other active substances.</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-29739</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-12121</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-33884</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10777</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-82774</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-33885</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-29739</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29739-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Gonciar</cfFamilyNames> <cfFirstNames>Veaceslav</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-12121</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-12121-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Scutar</cfFamilyNames> <cfFirstNames>Corina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-33884</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-33884-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Peredelcu</cfFamilyNames> <cfFirstNames>Rodica</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10777</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10777-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Cazacu</cfFamilyNames> <cfFirstNames>Vasilii</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-82774</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-82774-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Popa</cfFamilyNames> <cfFirstNames>Cristina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-33885</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-33885-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Scutari</cfFamilyNames> <cfFirstNames>Oleg</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>